RADIOPHARM THERANOSTICS LIMITED(RAD)

The suspension of trading in the securities of Radiopharm Theranostics Limited will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

The company releases a notice of proposed issue of securities.

The company releases its Lantheus Strategic Investment and Capital Raise Presentation.

Radiopharmaceutical industry leader, Lantheus Holdings, Inc., has agreed to make an initial strategic equity investment of A$7.5m at A$0.05 per share, which represents a 47% premium to last closing price of A$0.034 on 19 June 2024. Two Tranche Placement to raise an additional A$62.5m, taking total amount raised under the placement to A$70.0m. Offer price for shares issued under the balance of the placement of A$0.04 represents an 18% premium to the last closing price. Participation from leading international institutional investors including US specialist healthcare investors. Net proceeds are expected to fully fund the current clinical programs until the end of 2026. Executive Chair, Paul Hopper, to participate in the placement with A$3.0 million investment, subject to shareholder approval. Option for Lantheus to invest a further A$7.5m within 6 months on the same terms. Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement.

The securities of Radiopharm Theranostics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAD, pending the release of an announcement regarding its proposed capital raising.

The suspension of trading in the options of Radiopharm Theranostics Limited will be lifted immediately.

The options of Radiopharm Theranostics Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Monday, 28 November 2022. The suspension only applies to RAD's options and does not apply to any other quoted securities of RAD.

The suspension of trading in the securities of Radiopharm Theranostics Limited will be lifted immediately following the release by RAD of an announcement regarding the completion of its institutional entitlement offer.

The company releases a supplementary prospectus.

Successful completion of the institutional component of the accelerated non-renounceable entitlement offer originally announced on 19 October 2022, raising approximately $5.5 million. Bell Potter Securities Limited has committed to fully underwrite the retail component of the Entitlement Offer of approximately $4.5m, providing certainty that approximately $10.0 million will be raised under the Offer. Proceeds raised from the Entitlement Offer provides the Company with runway until at least the end of 2023, including 3 new assets acquired since IPO, As announced on 18 October 2022, Radiopharm's Pivalate delivers positive Phase 2a data in its brain mets trial. The Company is expected to have five fully funded Phase 1 clinical trials underway by the beginning of 2023, whilst progressing Pivalate into late-stage trials in the US.

The company releases an updated notice of proposed issue of securities.

The company releases its presentation on the entitlement offer..

Radiopharm is undertaking a 1 for 3.55 accelerated non-renounceable entitlement offer to raise up to $10 million (before costs) at A$0.14 per New Share. Provides the Company with runway until at least the end of 2023, including 3 new assets acquired since IPO. Entitlement offer participants will receive 1 new option for every New Share issued under the offer "“ the options will have exercise price of A$0.20 and expiry date of 30 November 2026. Chairman, Paul Hopper, has committed to subscribe for A$500,000 under the Offer and CEO, Riccardo Canevari, has subscribed for approximately A$170,000. As announced on 18 October 2022, Radiopharm's Pivalate delivers positive Phase 2a data in its brain mets trial. The Company is expected to have five fully funded Phase 1 clinical trials underway by the beginning of 2023, whilst progressing Pivalate into late-stage trials in the US.

The company issues a prospectus for an accelerated non-renounceable pro rata entitlement offer of 1 New Share for every 3.55 Existing Shares (and 1 New Option for every New Share issued) at an Offer Price of $0.14 to raise up to approximately $10 million (before the exercise of any New Options).

The company releases a notice of proposed issue of securities

The company will host an investor webinar on the Pivalate positive Phase 2 data, for which Radiopharm acquired an exclusive worldwide licence. The webinar will be held today, Tuesday 18 October 2022 at 3:30pm AEDT.

The company releases a presentation for the Pivalate achieves positive Phase 2 data.

F-18 Pivalate PET shows high uptake regardless of origin of primary tumour. F-18 Pivalate can be used to monitor cerebral metastases. Patients without previous external beam radiation show higher tumour uptake, while those previously treated show a trend towards lower uptake.

The securities of Radiopharm Theranostics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAD, pending the release of an announcement regarding the analysis of the Pivalate Phase II Data in Brain Mets Trial.

listed entity carried for record purposes only